Epigenetic analysis of 6-base genome in Parkinson’s
31 Jul 2025
The emergence of the ‘6-base genome’, which includes the modified bases 5-methylcytosine (5mC) and its oxidised form, 5-hydroxymethylcytosine (5hmC), marks a significant evolution in our understanding of genetic and epigenetic regulation.
In this webinar, Burleen Chhatwal from University College London, UK, demonstrates how biomodal’s 6-base genome supported the successful analysis of both 5mC and 5hmC modifications in Parkinson’s disease compared to controls in a pilot study.
About the company
biomodal
biomodal is an omics-based life sciences technology and analytics company delivering products that bring the dynamism of our ever-changing biology into focus. Our duet multiomics solution enables more epigenetic information from a single, low input DNA library without complex, resource intensive bioinformatics or harsh chemical treatment. Our single-base-resolution, phased sequencing approach unlocks the combinatorial power of genetic and epigenetic information in one workflow, elucidating greater biological insight within the fields of cancer, neurodegenerative disease, and ageing.
Related products
Request Quote for All Products
duet multiomics solution evoC
biomodalYour single solution for multiomics data - Uncover a true 6-base genome for unprecedented insights into current and future biological states. Access all four canonical bases and distinguish 5‑methylcytosine (5mC) and 5‑hydroxymethylcytosine (5hmC) from a single 5ng DNA sample, in a single experiment, with high accuracy.
